New Reference: Cemiplimab for Cervical Cancer
Study
Open-label, multicenter, phase 3 trial (EMPOWER-Cervical 1)
|
Recurrent or metastatic cervical carcinoma, progressed after prior platinum-containing therapy
|
Cemiplimab (n=304) or single-agent chemotherapy (n=304)
|
Efficacy
mOS: 12.0 mos vs. 8.5 mos; (HR: 0.69; P<0.001)
|
ORR: 16.4% vs 6.3%
|
Safety
Grade 3 AE >= 45% vs 53.4
|
Anemia:12% vs 26.9%. Urinary tract infection 5.0% vs 2.8%
|
Survival with Cemiplimab in Recurrent Cervical Cancer
Reviewed by Hasan Cagri Yildirim, MD on May 20, 2022
